Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Renal insufficiency in patients with multiple myeloma

Renal insufficiency in patients with multiple myeloma Summary Renal insufficiency in patients with multiple myeloma represents a major challenge for the treating physician. In patients with etiologically unclear renal failure it is important to consider multiple myeloma as a possible cause of such renal failure. The diagnosis and treatment of these patients is interdisciplinary, in cooperation with hemato-oncologists, radiologists, nephrologists and intensive care specialists. The main goal of all treatment methods is the rapid reduction of pathological free light chains in the serum, resulting in an improvement of renal function. Equally important is the avoidance of nephrotoxic drugs and iodinated contrast agents in patients with renal insufficiency and multiple myeloma. A few new drugs have been used in the systemic treatment of patients with multiple myeloma (MM) and renal failure with much success, especially the beneficial use of pomalidomide is interesting and other drugs will follow soon. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Renal insufficiency in patients with multiple myeloma

Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/renal-insufficiency-in-patients-with-multiple-myeloma-zNkskwaquT
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0343-3
Publisher site
See Article on Publisher Site

Abstract

Summary Renal insufficiency in patients with multiple myeloma represents a major challenge for the treating physician. In patients with etiologically unclear renal failure it is important to consider multiple myeloma as a possible cause of such renal failure. The diagnosis and treatment of these patients is interdisciplinary, in cooperation with hemato-oncologists, radiologists, nephrologists and intensive care specialists. The main goal of all treatment methods is the rapid reduction of pathological free light chains in the serum, resulting in an improvement of renal function. Equally important is the avoidance of nephrotoxic drugs and iodinated contrast agents in patients with renal insufficiency and multiple myeloma. A few new drugs have been used in the systemic treatment of patients with multiple myeloma (MM) and renal failure with much success, especially the beneficial use of pomalidomide is interesting and other drugs will follow soon.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Sep 1, 2017

References

  • Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety
    AZ Badros, R Vij, T Martin, JA Zonder
  • Randomized multicenter phase II study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
    RC Baz, TG Martin, HY Lin
  • Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
    L Benboubker, MA Dimopoulos, A Dispenzieri, J Catalano, AR Belch, M Cavo
  • Pharmacokinetics and safety of Elotuzumab combined with Lenalidomide and Dexamethasone in patients with multiple myeloma and various levels of renal impairment: Results of a phase Ib study
    J Berdeja
  • Treatment of myeloma cast Nephropathy (MCN): A randomized trial comparing intensive Haemodialysis (HD) with high cut-off (HCO) or standard high-flux dialyzer in patients receiving a Bortezomib-based regimen (the MYRE study, by the Intergroupe Francophone du Myélome (IFM) and the french society of Nephrology (SFNDT))
    F Bridoux, B Pegourie, KA Meunier, B Royer, B Joly, T Lamy, B Kolb, L Benboubker, B Arnulf, A Jaccard, S Chevret, JP Fermand
  • Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities
    A Davenport, G Merlini
  • International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment
    MA Dimopoulos
  • Cardiac and renal complications of carfilzomib in patients with multiple myeloma
    MA Dimopoulos, M Roussou
  • Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3
    M Dimopoulos, R Kyle, JP Fermand, SV Rajkumar, J Miguel, A Chanan-Khan
  • Pathogenesis and treatment of renal failure in multiple myeloma
    MA Dimopoulos, E Kastritis, L Rosinol, J Bladé, H Ludwig
  • Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents
    MA Dimopoulos, S Delimpasi, E Katodritou, A Vassou
  • Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
    MA Dimopoulos, X Leleu, A Palumbo, P Moreau, M Delforge, M Cavo, H Ludwig
  • Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma
    MA Dimopoulos, A Oriol, H Nahi, J San-Miguel
  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
    A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig
  • European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
    M Engelhardt, E Terpos, M Kleber
  • A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
    N Gupta
  • European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial
    CA Hutschison, M Cook, N Heyne, K Weisel, L Billingham, A Bradwell, P Cockwell
  • Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: A multicenter phase 1/2 open-label study
    A Larocca, V Montefusco, S Bringhen
  • Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant
    CK Lee, M Zangari, B Barlogie, A Fassas, F Rhee, R Thertulien
  • IMWG consensus on maintenance therapy in multiple myeloma
    H Ludwig, BGM Durie
  • Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma
    H Ludwig, J Drach, H Graf, A Lang, JG Meran
  • Light chain–induced acute renal failure Can be reversed by Bortezomib-Doxorubicin-Dexamethasone in multiple myeloma: Results of a phase II study
    H Ludwig, Z Adam, R Hajek
  • International Myeloma Working Group recommendations for global myeloma care
    H Ludwig, JS Miguel, MA Dimopoulos, A Palumbo
  • Lenalidomide and dexamethasone for acute light chain-induced renal failure: A phase II study
    H Ludwig, E Rauch, T Kuehr
  • Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
    JF Miguel
  • Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies
    JJ Montseny, D Kleinknecht, A Meyrier
  • Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma
    A Palumbo, A Chanan-Khan, K Weisel
  • Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management
    SV Rajkumar
  • Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial
    P Sonneveld